Quattro Advisors’s Gilead Sciences GILD Stock Holding History

Quattro Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-209	Closed	-$25.7K	–	248
2025 Q4	$25.7K	Buy	+209	New	+$25.4K	0.02%	161

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Quattro Advisors's GILD Position: Q1 2026 in Review

Quattro Advisors sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 209 shares — an estimated $25.7K sold.

Quattro Advisors first reported a position in GILD in Q4 2025 and held it in 1 quarter. The position peaked at $25.7K in Q4 2025. 2,320 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Quattro Advisors reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
Quattro Advisors sold 209 Gilead Sciences shares in Q1 2026, an estimated $25.7K.
Quattro Advisors first reported a position in Gilead Sciences in Q4 2025 and held it in 1 quarter.
Quattro Advisors's Gilead Sciences position peaked at $25.7K in Q4 2025.
2,320 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Quattro Advisors's 13F filing for Q1 2026, filed 15 May 2026.